New Product for Lowering Cholesterol

Here is a News Release regarding a new product for lowering cholesterol that even has clinical trials with it proving it works. This is not a drug but a food supplement with out sideffects. Please contact me if you would like more information about this product when it becomes availble.

Greg Murphy
gamurphy64@yahoo.com


NEWS RELEASE

FOR FURTHER INFORMATION, CONTACT:

David G. Kreher Fred Nielson Al Palombo
Chief Operating Officer Investor Relations Cameron Associates
(636) 537-9715 (636) 733-1314 (212) 554-5488


RELIV INTERNATIONAL ANNOUNCES RELEASE OF
CLINICAL STUDY RESULTS ON NEW PRODUCT


Study Shows Product Is Effective in Significantly Reducing
Elevated Total Blood Cholesterol Levels


CHESTERFIELD, MO, January 12, 2005 -- Relìv International, Inc. (Nasdaq/NM - RELV), an international manufacturer and network marketer of nutritional supplements and food products, announced the release of results of an independent clinical trial on a dietary supplement newly developed by Reliv scientists.

The clinical trial was conducted under the direction of Joe Vinson, Ph.D., a Professor of Chemistry at the University of Scranton. Dr. Vinson has over 25 years of research and clinical experience with dietary supplements. The study sought to determine whether long-term supplementation with the use of Reliv’s new formulation would have an influence on plasma lipids in subjects with elevated cholesterol levels, in a double-blind, placebo crossover design.

The results of the trial showed statistically significant decreases in participants’ bad cholesterol (LDL) and triglyceride levels, decreases in the cholesterol/good cholesterol (HDL) ratio and decreases in the bad to good (LDL/HDL) ratios. Subjects participating in the trial initially were identified as having undesirable cholesterol ratios but, after a period of supplementation with the Reliv formulation, had achieved desirable levels. In addition, the trial results also showed improvement in cholesterol levels for those participants who were already taking statin (cholesterol-reducing) drugs.

The summary report on the clinical trial states that the overall effect of the program for participants in the study was a significant reduction in the 10-year risk of developing cardiovascular disease.

“Almost 700,000 people die annually in the United States from heart disease,” reported Dr. Carl W. Hastings, Vice President for Research and Development of Reliv, who participated in development of the Reliv formulation. “Heart disease is the number one cause of death in the United States and diagnosed heart disease occurs in 11% of non-institutionalized adults. High blood cholesterol is a major risk factor for coronary heart disease,” he said. “Our goal in developing this new formulation has been to address the serious health risks caused by elevated cholesterol levels in such a high proportion of our population.”

“The clinical trial on this new formulation has established not only its efficacy but also included testing which establishes the safety of the formulation for use by the participants,” reported David Barnes, Vice President Technical Affairs and Manufacturing Operations.

Reliv plans to introduce the new product at its Phoenix Leadership Conference on February 5, 2005.

Reliv distributes its products exclusively through its network of independent distributors in the United States and 9 other countries. Tweet